McMillan Shakespeare Ltd (ASX: MMS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
McMillan Shakespeare Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$1.36 billion
P/E Ratio
12.64
Dividend Yield
6.84%
Shares Outstanding
69.64 million
Earnings per share
1.527
Dividend per share
1.40
Year To Date Return
20.94%
Earnings Yield
7.91%
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
McMillan Shakespeare Ltd (ASX: MMS)
Latest News
ASX Share Market News
5 things to watch on the ASX 200 on Friday
Dividend Investing
40 ASX shares with ex-dividend dates next week
Earnings Results
McMillan Shakespeare shares on watch on strong FY26 profit and 70c dividend
Industrials Shares
Is this ASX industrials stock a buy, hold or sell after soaring 6% yesterday?
Dividend Investing
32 ASX shares about to go ex-dividend
Earnings Results
Bell Potter just upgraded these ASX 300 shares to a buy after earnings results
Earnings Results
This ASX 300 stock has shed over 5% following half-year results
Dividend Investing
Three under-the-radar dividend plays for your portfolio
Consumer Staples & Discretionary Shares
Macquarie has singled out the automotive stocks they say are worth a look
Dividend Investing
35 ASX shares with ex-dividend dates next week
Superannuation
10 most popular ASX shares being bought by self-managed superannuation investors in FY26
ASX Share Market News
Which ASX shares are wealthy investors buying in FY26?
Frequently Asked Questions
-
Yes, McMillan Shakespeare historically pays two fully franked dividends a year.
-
McMillan Shakespeare generally pays its shareholder dividends in March and September.
-
McMillan Shakespeare Ltd was listed on the ASX on 15 March 2004.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 10 Sep 2026 | $0.7000 | 100.00% | Final | 25 Sep 2026 |
| 12 Mar 2026 | $0.6200 | 100.00% | Interim | 27 Mar 2026 |
| 11 Sep 2025 | $0.7700 | 100.00% | Final | 26 Sep 2025 |
| 13 Mar 2025 | $0.7100 | 100.00% | Interim | 28 Mar 2025 |
| 12 Sep 2024 | $0.7800 | 100.00% | Final | 27 Sep 2024 |
| 07 Mar 2024 | $0.7600 | 100.00% | Interim | 22 Mar 2024 |
| 07 Sep 2023 | $0.6600 | 100.00% | Final | 22 Sep 2023 |
| 09 Mar 2023 | $0.5800 | 100.00% | Final | 24 Mar 2023 |
| 26 Oct 2022 | $0.7400 | 100.00% | Final | 10 Nov 2022 |
| 10 Mar 2022 | $0.3400 | 100.00% | Interim | 25 Mar 2022 |
| 09 Sep 2021 | $0.3110 | 100.00% | Final | 24 Sep 2021 |
| 11 Mar 2021 | $0.3020 | 100.00% | Interim | 26 Mar 2021 |
| 05 Mar 2020 | $0.3400 | 100.00% | Interim | 20 Mar 2020 |
| 28 Aug 2019 | $0.4000 | 100.00% | Final | 11 Sep 2019 |
| 07 Mar 2019 | $0.3400 | 100.00% | Interim | 22 Mar 2019 |
| 13 Sep 2018 | $0.4000 | 100.00% | Final | 28 Sep 2018 |
| 15 Mar 2018 | $0.3300 | 100.00% | Interim | 29 Mar 2018 |
| 28 Sep 2017 | $0.0000 | 100.00% | Final | 13 Oct 2017 |
| 30 Mar 2017 | $0.3100 | 100.00% | Interim | 13 Apr 2017 |
| 29 Sep 2016 | $0.3400 | 100.00% | Final | 14 Oct 2016 |
| 31 Mar 2016 | $0.2900 | 100.00% | Interim | 15 Apr 2016 |
| 16 Sep 2010 | $0.1400 | 100.00% | Final | 15 Oct 2010 |
| 08 Mar 2006 | $0.0250 | 100.00% | Interim | 29 Mar 2006 |
| 18 Aug 2005 | $0.0240 | 100.00% | Final | 16 Sep 2005 |
MMS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About McMillan Shakespeare Ltd
McMillan Shakespeare Ltd (ASX: MMS) is an employee benefits provider. Its services include salary packaging, novated leasing, disability plan management and support coordination, asset management, and related financial products and services.
The company's asset management businesses provide motor vehicle leasing and fleet management services, as well as fleet and consumer financing.
McMillan Shakespeare consists of more than 20 subsidiaries, the majority incorporated in Australia but also in New Zealand and the United Kingdom.
MMS Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 04 Nov 2026 | $19.32 | $0.02 | 0.10% | 329,073 | $19.35 | $19.47 | $18.93 |
| 03 Nov 2026 | $19.30 | $-1.13 | -5.53% | 571,122 | $20.13 | $20.41 | $19.09 |
| 02 Nov 2026 | $20.43 | $0.20 | 0.99% | 245,652 | $20.10 | $20.50 | $20.09 |
| 30 Oct 2026 | $20.23 | $0.16 | 0.80% | 222,441 | $20.15 | $20.45 | $20.00 |
| 29 Oct 2026 | $20.07 | $-0.19 | -0.94% | 215,381 | $20.20 | $20.39 | $19.94 |
| 28 Oct 2026 | $20.26 | $-0.25 | -1.22% | 255,947 | $20.38 | $20.50 | $19.91 |
| 27 Oct 2026 | $20.51 | $0.64 | 3.22% | 608,140 | $19.95 | $20.60 | $19.85 |
| 26 Oct 2026 | $19.87 | $0.08 | 0.40% | 302,807 | $19.70 | $19.97 | $19.61 |
| 23 Oct 2026 | $19.79 | $0.50 | 2.59% | 213,072 | $19.31 | $19.83 | $19.19 |
| 22 Oct 2026 | $19.29 | $0.59 | 3.16% | 484,523 | $18.74 | $19.52 | $18.53 |
| 21 Oct 2026 | $18.70 | $0.14 | 0.75% | 325,707 | $18.47 | $18.73 | $18.45 |
| 20 Oct 2026 | $18.56 | $-0.17 | -0.91% | 75,812 | $18.70 | $18.70 | $18.41 |
| 19 Oct 2026 | $18.73 | $0.25 | 1.35% | 180,146 | $18.40 | $18.82 | $18.32 |
| 16 Oct 2026 | $18.48 | $0.04 | 0.22% | 98,337 | $18.51 | $18.58 | $18.24 |
| 15 Oct 2026 | $18.44 | $0.12 | 0.66% | 209,077 | $18.33 | $18.64 | $18.14 |
| 14 Oct 2026 | $18.32 | $-0.25 | -1.35% | 140,926 | $18.51 | $18.54 | $18.16 |
| 13 Oct 2026 | $18.57 | $0.17 | 0.92% | 90,165 | $18.69 | $18.69 | $18.41 |
| 12 Oct 2026 | $18.40 | $-0.38 | -2.02% | 85,321 | $18.78 | $18.79 | $18.39 |
| 09 Oct 2026 | $18.78 | $0.48 | 2.62% | 98,049 | $18.30 | $18.78 | $18.26 |
| 08 Oct 2026 | $18.30 | $0.03 | 0.16% | 56,047 | $18.10 | $18.36 | $18.10 |
| 07 Oct 2026 | $18.27 | $0.28 | 1.56% | 219,234 | $18.00 | $18.42 | $18.00 |
| 06 Oct 2026 | $17.99 | $-0.01 | -0.06% | 75,369 | $17.93 | $18.11 | $17.91 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 08 Sep 2026 | Robert (Rob) De Luca | Buy | 43,533 | $861,082 |
Conversion of securities.
|
| 08 Sep 2026 | Robert (Rob) De Luca | Transfer | 91,232 | $1,804,568 |
Off-market transfer. Assuming off market transfer of shares
|
| 08 Sep 2026 | Robert (Rob) De Luca | Transfer | 91,232 | $1,804,568 |
Off-market transfer. Assuming off market transfer of shares
|
| 08 Sep 2026 | Robert (Rob) De Luca | Exercise | 43,533 | $861,082 |
Conversion of securities. 108,444 rights
|
| 08 Sep 2026 | Robert (Rob) De Luca | Expiry | 7,713 | $152,563 |
As advised by the company. 100,731 performance rights, 7,713 rights lapsed
|
| 05 Dec 2025 | Robert (Rob) De Luca | Issued | 55,123 | $951,422 |
Director remuneration. 1,51,977 Rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Bruce John Akhurst | Non-Executive Director | Apr 2021 |
Mr Akhurst is currently the Chair of the Peter McCallum Cancer Foundation. He is the chairperson of the People and Culture Committee and member of the risk and compliance Committee.
|
| Mr John G Bennetts | Non-Executive Director | Dec 2003 |
Mr Bennetts is an investor and has been the founder and director of a number
of Australian companies. He owns businesses in varied industries including technology and finance. He was a founder of multi-national biotechnology company, Cellestis Limited and private equity investment firm, Mooroolbark Investments Pty Limited (M-Group). |
| Ms Helen Kurincic | Non-Executive DirectorNon-Executive Chairman | Sep 2018 |
Ms Kurincic's Past management roles include Chief Operating Officer and Director of Genesis Care from its earliest inception, creating and developing the first radiation oncology and cardiology business across Australia, CEO of Heart Care Victoria and CEO of Benetas. She is the member of the Risk and Compliance Committee and people and culture committee.
|
| Ms Arlene May Tansey | Non-Executive Director | Nov 2022 |
Ms Tansey worked in commercial and investment banking in Australia (ANZ Banking Group and Macquarie Bank) and in investment banking and law in the United States. She is a member of Chief Executive Women and the International Women's Forum. She is the member of the Risk and Compliance Committee and People and Culture Committee.
|
| Mr Robert (Rob) De Luca | Chief Executive OfficerManaging Director | May 2022 |
Mr De Luca d has over 25 years'experience in the Financial Services, Wealth Management, Disability and Healthcare sectors, including roles as Managing Director of Bankwest, and CEO of the National Disability Insurance Agency (NDIA). Prior to joining MMS, Mr De Luca was CEO of Zenitas Healthcare.
|
| Ms Kathryn Maree Parsons | Non-Executive Director | May 2020 |
Ms Parsons has accounting, finance, governance and risk management expertise. She is the chairperson of the Risk and Compliance Committee and member of the People and Culture Committee.
|
| Mr Andrew Geoffrey Moore | Non-Executive Director | Sep 2026 |
Mr Moore is currently a Non-Executive Director of RACQ Limited, Helia Group Limited (ASX:HLI) and Spaceship Capital Limited. Mr Moore is a financial services executive with domestic and global experience across finance, banking, wealth management and financial technology. In his executive career, Mr Moore was recently CEO of Spaceship Financial Services. Prior to this, Mr Moores executive career involved various senior executive roles at Westpac, St.George Bank and GE Capital. Key roles included: GM Customer Experience and Contact Centres at Westpac GM Retail Banking at St.George,Zand Managing Director of GE Capitals home lending business in Australia and New Zealand. Earlier in his career, Mr Moore worked in GE Capital in house M&A team in London, and in investment banking and corporate advisory roles at Bankers Trust and Coopers & Lybrand.Mr Moore will be a member of the Risk and Compliance Committee
|
| Ms Michelle Siekierka | General CounselCompany Secretary | Oct 2025 |
-
|
| Michelle Siekierka | General CounselCompany Secretary |
-
|
|
| P Varro | Group CFO |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Aust) Ltd | 13,896,207 | 19.95% |
| Citicorp Nominees Pty Limited | 7,388,631 | 10.61% |
| Chessari Holdings Pty Ltd | 6,050,941 | 8.69% |
| J P Morgan Nominees Australia Pty Limited | 5,480,862 | 7.87% |
| Asia Pac Technology Pty Ltd | 3,068,025 | 4.41% |
| UBS Nominees Pty Ltd | 1,173,611 | 1.69% |
| BNP Paribas Noms Pty Ltd | 1,124,290 | 1.61% |
| Ann Leslie Ryan | 1,008,418 | 1.45% |
| Tarrina Holdings Pty Ltd <Tarrina Holding S/F A/C> | 719,217 | 1.03% |
| Mohl Invest Pty Ltd <Mohl Super Fund A/C> | 600,000 | 0.86% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 362,535 | 0.52% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 296,019 | 0.43% |
| Birdseye No2 Management Pty Ltd <Birdseye Super No2 Fund A/C> | 260,000 | 0.37% |
| Mestjo Pty Ltd | 214,790 | 0.31% |
| Mod Enterprises Pty Ltd | 182,000 | 0.26% |
| Mohl Invest Pty Ltd <Mohl Family A/C> | 150,000 | 0.22% |
| Garmaral Pty Ltd | 137,277 | 0.20% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 132,503 | 0.19% |
| BNP Paribas Noms Pty Ltd <Global Markets> | 130,776 | 0.19% |
| Dgmh Super Pty Ltd <Lethbridge Super A/C> | 130,105 | 0.19% |
